Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has been assigned a $18.00 price target by equities researchers at Raymond James Financial, Inc. in a note issued to investors on Wednesday, August 9th. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Raymond James Financial, Inc.’s price target suggests a potential upside of 131.66% from the company’s current price.
Several other research firms have also issued reports on BLCM. Wells Fargo & Company restated an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Cantor Fitzgerald restated an “overweight” rating and set a $35.00 price target on shares of Bellicum Pharmaceuticals in a research report on Monday, June 26th. Ladenburg Thalmann Financial Services set a $31.00 price target on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, June 24th. Jefferies Group LLC reduced their price target on Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 9th. Finally, BidaskClub cut Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Bellicum Pharmaceuticals currently has an average rating of “Hold” and an average price target of $26.20.
Bellicum Pharmaceuticals (NASDAQ BLCM) traded up 1.97% during trading on Wednesday, hitting $7.77. The company had a trading volume of 472,652 shares. Bellicum Pharmaceuticals has a 1-year low of $7.41 and a 1-year high of $23.11. The stock’s market capitalization is $258.17 million. The company’s 50 day moving average price is $10.61 and its 200-day moving average price is $12.15.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period in the prior year, the business earned ($0.61) EPS. On average, analysts expect that Bellicum Pharmaceuticals will post ($3.00) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/bellicum-pharmaceuticals-inc-blcm-given-a-18-00-price-target-by-raymond-james-financial-inc-analysts-updated.html.
In other news, CFO Alan A. Musso sold 6,311 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $12.24, for a total value of $77,246.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the completion of the transaction, the vice president now owns 14,314 shares of the company’s stock, valued at approximately $175,489.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,571 shares of company stock valued at $367,295. Company insiders own 23.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLCM. California State Teachers Retirement System boosted its position in Bellicum Pharmaceuticals by 16.7% in the second quarter. California State Teachers Retirement System now owns 48,146 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 6,900 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Bellicum Pharmaceuticals by 26.6% in the second quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 4,684 shares during the last quarter. State Street Corp boosted its position in Bellicum Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock worth $4,872,000 after buying an additional 59,321 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Bellicum Pharmaceuticals by 223.5% in the second quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock worth $1,612,000 after buying an additional 95,336 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter worth approximately $448,000. Institutional investors own 63.97% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
What are top analysts saying about Bellicum Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellicum Pharmaceuticals Inc. and related companies.